NARCOLEPSY
Clinical trials for NARCOLEPSY explained in plain language.
Never miss a new study
Get alerted when new NARCOLEPSY trials appear
Sign up with your email to follow new studies for NARCOLEPSY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Narcolepsy patients may see blood pressure benefits by switching to Low-Sodium oxybate
Disease control CompletedThis study involved 155 adults with narcolepsy who were already taking a high-sodium oxybate medication. They switched to Xywav, a low-sodium version, to see if their blood pressure would improve. The goal was to provide doctors and patients with useful information about the impa…
Matched conditions: NARCOLEPSY
Phase: PHASE4 • Sponsor: Jazz Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Dream control: a new behavioral approach to tame narcolepsy nightmares
Symptom relief CompletedThis study tests two behavioral therapies—imagery rehearsal therapy (IRT) and targeted dream control (TDC)—to reduce nightmares in adults with narcolepsy. Participants attend therapy sessions, keep a daily sleep log, and complete questionnaires. Some Chicago-area participants als…
Matched conditions: NARCOLEPSY
Phase: NA • Sponsor: Northwestern University • Aim: Symptom relief
Last updated Jul 01, 2026 23:00 UTC
-
New drug shows promise for Narcolepsy's worst symptoms
Symptom relief CompletedThis Phase 2 trial tested AXS-12 (reboxetine) in 21 adults with narcolepsy and cataplexy. Participants received either the drug or a placebo for three weeks, then switched. The goal was to see if AXS-12 could reduce weekly cataplexy attacks and improve excessive daytime sleepines…
Matched conditions: NARCOLEPSY
Phase: PHASE2 • Sponsor: Axsome Therapeutics, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
New pill aims to stop Narcolepsy's sudden muscle weakness
Symptom relief CompletedThis study tested an experimental drug called AXS-12 (reboxetine) in 90 people with narcolepsy who experience cataplexy (sudden muscle weakness) and excessive daytime sleepiness. Participants took either the drug or a placebo twice daily for several weeks. The main goal was to se…
Matched conditions: NARCOLEPSY
Phase: PHASE3 • Sponsor: Axsome Therapeutics, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 12:38 UTC
-
New sleep drug shows promise for narcolepsy patients
Symptom relief CompletedThis study followed 71 adults with narcolepsy who started taking LUMRYZ, a medication for excessive daytime sleepiness. Over 4 months, participants filled out questionnaires about their symptoms, how they felt about the drug, and their quality of life. The goal was to see if LUMR…
Matched conditions: NARCOLEPSY
Sponsor: Avadel • Aim: Symptom relief
Last updated Jun 27, 2026 09:04 UTC
-
New Slow-Release pill for narcolepsy passes early safety check
Symptom relief CompletedThis early-phase study tested a new slow-release form of pitolisant (HBS-201) in 46 adults with narcolepsy. The goal was to see if starting at a full dose is tolerable. Participants took the drug for 14 days, and researchers tracked side effects and dropouts.
Matched conditions: NARCOLEPSY
Phase: PHASE1 • Sponsor: Harmony Biosciences Management, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 08:03 UTC
-
New drug shows promise for reducing narcolepsy attacks over the long term
Symptom relief CompletedThis study looked at the long-term safety and effectiveness of a drug called AXS-12 for people with narcolepsy who also have sudden muscle weakness (cataplexy) and severe daytime sleepiness. 68 people who had already completed an earlier study took AXS-12 and were monitored for s…
Matched conditions: NARCOLEPSY
Phase: PHASE3 • Sponsor: Axsome Therapeutics, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 07:57 UTC
-
New Once-Nightly pill could simplify narcolepsy treatment
Symptom relief CompletedThis study tested a new once-nightly medication called FT218 for people with narcolepsy who experience excessive daytime sleepiness and sudden muscle weakness (cataplexy). It included 184 participants, some already on a twice-nightly medication and some new to treatment. The goal…
Matched conditions: NARCOLEPSY
Phase: PHASE3 • Sponsor: Avadel • Aim: Symptom relief
Last updated Jun 27, 2026 07:53 UTC
-
Anxiety and job factors may influence sleepiness tests
Knowledge-focused CompletedThis study looked at 103 adults with narcolepsy or obstructive sleep apnea to see if anxiety, social, or work factors affect their ability to stay awake during a standard test. Participants filled out an anxiety questionnaire before the test. The goal is to better understand why …
Matched conditions: NARCOLEPSY
Sponsor: Hospices Civils de Lyon • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:03 UTC
-
Can a wakefulness drug make driving safer for sleepy patients?
Knowledge-focused CompletedThis study looked at how the drug modafinil affects driving ability in 27 people with narcolepsy or hypersomnia. Participants took modafinil or a placebo for five days, then completed both simulated and real driving tests. The goal was to see if the drug improves alertness and re…
Matched conditions: NARCOLEPSY
Phase: NA • Sponsor: University Hospital, Bordeaux • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
Narcoleptic Kids' weight gain mystery: is metabolism to blame?
Knowledge-focused CompletedThis study looked at 24 children (ages 6-17) with narcolepsy or hypersomnia to see if changes in their metabolism explain why they often gain weight and become obese. Researchers measured energy use at home and in the hospital using activity trackers. The goal was to understand t…
Matched conditions: NARCOLEPSY
Phase: NA • Sponsor: Hospices Civils de Lyon • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:05 UTC